Financial Data and Key Metrics Changes - Revenues for the nine months ended December 31, 2025, totaled $887,000, a decrease of 2% from the same year-ago period [17] - Gross profit for the first nine months was $551,500, or 62.2% of revenues, down from 89% of revenues in the same period a year ago [19] - Net loss for the first nine months was $7.5 million, or 27 cents per share, compared to a net loss of $6 million, or 30 cents a share for the same year-ago period [22] - Total operating expenses decreased 2% to $6.7 million compared to the same year-ago period [21] - Current assets totaled $1.4 million, while current liabilities significantly reduced to $980,000 from $4.2 million a year ago [23][24] Business Line Data and Key Metrics Changes - Sales of Spryng products totaled $400,800, while sales of PrecisePRP products totaled $486,000, indicating a shift in sales mix [17] - The decrease in revenues was primarily due to a decline in Spryng product sales, offset by an increase in PrecisePRP sales [18] - The company plans to re-implement special promotions to incentivize distributors and veterinary clinics to improve Spryng sales [18] Market Data and Key Metrics Changes - The Canadian animal healthcare market is projected to grow at a CAGR of 6.8% to exceed $4.4 billion by 2031 [25] - The European animal health market is estimated at over $16.6 billion today and is projected to grow at a CAGR of 8.6% to $34.8 billion by 2033 [15] Company Strategy and Development Direction - The company is focusing on creating rapid growth and market expansion opportunities, including strong recurring revenues [2] - Strategic alliances with partners like Digital Landia aim to enhance the veterinary industry through innovative AI solutions [3] - The launch of PetVivo AI, an AI-powered software platform for veterinarians, is expected to provide a strong first-mover advantage [4] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, expecting continued sales momentum and market penetration for fiscal 2026 and beyond [31] - The company is in advanced discussions with an outside sales and marketing firm to enhance its distribution network [31] - Management highlighted the importance of educating customers on the combined benefits of Spryng and PrecisePRP to drive future sales [19] Other Important Information - The company appointed Josh Ruben to its board of directors, bringing extensive experience in healthcare and life sciences [16] - The partnership with Veterinary Growth Partners aims to promote Spryng and PrecisePRP products to over 7,300 veterinary clinics [8] Q&A Session Summary Question: Updates on getting on the NASDAQ listings - The company is working towards uplisting on the New York AMEX, contingent on stock price and market conditions [34] Question: Can you talk about the previous guidance given on last conference call? - Management indicated that previous guidance was around $2 million-$2.5 million for fiscal year, but recent sales trends have affected expectations [37][38] Question: Are you pushing out the uptick in sales? - Management clarified that the sales model has changed, and they are focusing on spreading sales more evenly across quarters [40] Question: Can you talk about the CapEx required for the rollout of the Digital Landia platform? - The onboarding process for veterinarians is streamlined, and CapEx is minimal as Digital Landia will handle most of the implementation [42][51] Question: Will PetVivo recognize revenues from the implementation of the veterinarian system? - Yes, the company expects to recognize revenues as veterinarians implement the system and benefit from cost savings [46] Question: Do you have expectations for revenues and PNL? - Management refrained from providing specific revenue guidance at this time [52][53]

Financial Data and Key Metrics Changes - Revenues for the nine months ended December 31, 2025, totaled $887,000, a decrease of 2% from the same period a year ago [17] - Gross profit for the first nine months was $551,500, or 62.2% of revenues, down from $812,000, or 89% of revenues in the same period a year ago [19] - Net loss for the first nine months was $7.5 million, or 27 cents per share, compared to a net loss of $6 million, or 30 cents per share for the same year-ago period [22] - Total operating expenses decreased 2% to $6.7 million compared to the same year-ago period [21] - Current assets totaled $1.4 million, while current liabilities significantly reduced to $980,000 from $4.2 million a year ago [23] Business Line Data and Key Metrics Changes - Sales of Spryng products totaled $400,800, while PrecisePRP products totaled $486,000, indicating a shift in sales mix [17] - The decrease in revenues was primarily due to a decline in Spryng sales, offset by an increase in PrecisePRP sales [18] - The company plans to re-implement special promotions to incentivize distributors and veterinary clinics to improve Spryng sales [18] Market Data and Key Metrics Changes - The Canadian animal healthcare market is projected to grow at a CAGR of 6.8% to exceed $4.4 billion by 2031 [25] - The European animal health market is estimated at more than $16.6 billion today and is projected to double to $34.8 billion by 2033, growing at a CAGR of 8.6% [14][15] Company Strategy and Development Direction - The company is focusing on creating rapid growth and market expansion opportunities, including strong recurring revenues [2] - Strategic alliances with partners like Digital Landia aim to enhance the veterinary industry through innovative AI solutions [3] - The launch of PetVivo AI, an AI-powered software platform for veterinarians, is expected to provide a strong first-mover advantage [4] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, expecting continued sales momentum and market penetration for the duration of fiscal 2026 and beyond [31] - The company is in advanced discussions with an outside sales and marketing firm to enhance its distribution network [31] - Management highlighted the importance of educating customers on the combined benefits of Spryng and PrecisePRP to drive future sales [19] Other Important Information - The company appointed Josh Ruben to its board of directors, bringing extensive experience in healthcare and life sciences [16] - The partnership with Veterinary Growth Partners aims to promote Spryng and PrecisePRP products to over 7,300 veterinary clinics [8] Q&A Session Summary Question: Updates on getting on the NASDAQ listings - The company is working towards listing on New York AMEX, with stock price being a factor in the timeline [34] Question: Previous guidance on revenue - Management indicated that previous guidance was around $2 million-$2.5 million for the fiscal year, but recent sales trends have affected expectations [37][38] Question: CapEx for the rollout of the Digital Landia platform - The onboarding of veterinarians will be part of the current clinics, with minimal CapEx required as Digital Landia will handle the system updates [42][51] Question: Revenue expectations from the implementation of the PetVivo.ai system - Management confirmed that revenues will be recognized from veterinarians implementing the system, which operates on a SaaS model [46][48]

Core Insights - PetVivo Holdings, Inc. has appointed Josh Ruben to its Board of Directors, enhancing its leadership team with expertise in healthcare finance and corporate strategy [1][2][4] - Ruben's background includes significant experience in executing multi-billion-dollar mergers and acquisitions, which will support PetVivo's growth and market expansion efforts [2][4] - The company focuses on innovative medical therapeutics for companion animals, particularly in treating osteoarthritis and joint conditions [2][6] Company Overview - PetVivo Holdings, Inc. operates in the biomedical device sector, specifically targeting the commercialization of medical devices and therapeutics for companion animals [6] - The company aims to leverage human therapies for animal treatment, allowing for a quicker market entry compared to traditional pharmaceuticals [6] - PetVivo has a diverse product pipeline, including its lead product SPRYNG, which utilizes OsteoCushion technology for joint-related afflictions in animals [7] Leadership and Strategy - Josh Ruben, as the Managing Director of Life Sciences at Trinity Capital, brings a wealth of experience in venture lending and investment banking, particularly in life sciences [4][5] - His expertise will be instrumental in guiding PetVivo's capital strategy and maximizing value creation across veterinary and emerging human applications [5] - The company holds a portfolio of twelve patents and six trade secrets, protecting its innovative biomaterials and production processes [7]